Product Details
GW-0742 is a synthetic compound classified as a peroxisome proliferator-activated receptor (PPAR) agonist. It is studied in controlled research environments for its interaction with nuclear receptor systems involved in transcriptional regulation.
Within laboratory settings, GW-0742 is utilized to examine receptor-ligand interactions and downstream signaling pathways associated with lipid-responsive transcription factors. Its chemical structure allows for consistent evaluation of binding dynamics and receptor activation at the molecular level.
This compound is supplied strictly for laboratory research purposes and is not intended for consumption, medical, or diagnostic use.
Mechanism of Action
At the molecular level, GW-0742 interacts with peroxisome proliferator-activated receptors (PPARs), which function as ligand-activated nuclear transcription factors. Upon binding, the compound-receptor complex undergoes conformational changes that facilitate interaction with specific DNA response elements.
This process is studied in vitro to evaluate transcriptional modulation and gene expression pathways regulated by PPAR activation. Researchers examine how ligand binding influences receptor cofactor recruitment and subsequent transcriptional activity.
Additionally, GW-0742 is used to investigate structure-dependent receptor selectivity and signaling behavior, contributing to a deeper understanding of nuclear receptor-mediated regulatory mechanisms under controlled experimental conditions.
Chemical Properties of GW-0742
| Attribute | Details |
| Compound Name | GW-0742 |
| Classification | PPAR agonist (nuclear receptor ligand) |
| Molecular Formula | C21H17F4NO3S2 |
| Molecular Weight | 471.49 g/mol |
| CAS Number | 317318-84-6 |
| IUPAC Name | [4-[[[2-[3-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenoxy]acetic acid |
| Synonyms | GW-0742 sulfoxide; GW0742 sulfone |
| Primary Target | Peroxisome proliferator-activated receptors (PPARs) |
| Research Context | Nuclear receptor signaling and transcriptional pathway analysis |
| Format | Research compound (non-consumable) |
| Stability | Stable under controlled laboratory storage conditions |
Research Applications
Nuclear Receptor Binding Studies
GW-0742 is utilized in experimental systems to analyze ligand interaction with PPARs. Researchers examine binding affinity and receptor activation at the molecular level.
Transcriptional Regulation Analysis
This compound is applied in studies investigating gene expression pathways influenced by nuclear receptor activation. These analyses focus on DNA-binding interactions and transcriptional modulation.
Structure-Activity Relationship Research
GW-0742 supports investigations into how molecular structure influences receptor selectivity and signaling behavior. These studies contribute to a broader understanding of ligand-receptor dynamics and nuclear signaling pathways.
Why Choose BehemothLabz to Buy GW-0742 for Research
BehemothLabz provides research-grade GW-0742 manufactured under controlled laboratory conditions with strict quality assurance protocols. Each batch undergoes analytical verification to ensure consistency in molecular composition and purity.
Comprehensive documentation, including laboratory testing reports and sourcing transparency, supports reproducibility in experimental settings. BehemothLabz maintains a compliance-focused approach, supplying compounds intended strictly for laboratory-based investigation and analytical research
Disclaimer
GW-0742 is intended strictly for laboratory research and analytical purposes only. It is not intended for use in diagnostic procedures, therapeutic applications, or in vivo studies of any kind.
Any references to biochemical pathways, receptor interactions, or enzymatic processes are provided solely for informational and research-context purposes. This compound must be handled exclusively by qualified professionals in controlled laboratory environments in accordance with applicable regulations and safety guidelines.
Improper handling or use outside of controlled research settings is strictly prohibited.
References
- Hamaya, R., Ogawa, M., Suzuki, J., Kobayashi, N., Hirata, Y., Nagai, R., Komuro, I., & Isobe, M. (2013). A selective peroxisome proliferator-activated receptor-β/δ agonist attenuates neointimal hyperplasia after wire-mediated arterial injury. Expert opinion on investigational drugs, 22(9), 1095–1106. https://doi.org/10.1517/13543784.2013.820702
- Yue, L., Jiang, N., Fan, X., Xu, S., Ren, Y., Lei, H., & Zhai, X. (2025). Rational design and synthesis of 6-(piperazin-1-yl)imidazo[1,2-b]pyridazine derivatives as dual FXR/PPARδ agonists for treatment of pulmonary fibrosis. European journal of medicinal chemistry, 298, 118013. https://doi.org/10.1016/j.ejmech.2025.118013
